Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.23.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 5 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 03, 2022
Jun. 30, 2023
Operating expenses:        
Research and development $ 3,027 $ 151 $ 1,959 $ 4,242
Research and development – licenses acquired 0 0 0 4,230
General and administrative 896 454 1,509 1,880
Loss from operations (3,923) (605) (3,468) (10,352)
Other income (expense)        
Interest income 57 1 3 94
Financing costs – warrant liabilities 0 0 0 (332)
Change in fair value of warrant liabilities (150) 0 0 (1,028)
Total other income (expense) (93) 1 3 (1,266)
Net loss (4,016) (604) (3,465) (11,618)
Net loss attributable to non-controlling interests 9 0 0 75
Net loss attributable to common stockholders $ (4,007) $ (604) $ (3,465) $ (11,543)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (0.52) $ (0.41) $ (2.42) $ (1.73)
Weighted average number of common shares outstanding, basic and diluted (in shares) 7,758,153 1,461,067 1,429,283 6,667,550